Complete, Fast, Non-Invasive Wound Care, Pain Relief & Quality Of Life Improvement
Clinical studies with D'OXYVA® (deoxyhemoglobin vasodilator) have shown extraordinary results for the role of transdermal CO2 in wound care.
The following images illustrate the typical example of D'OXYVA's efficacy as a stand-alone solution for closing chronic vascular disease-related wounds. All other advanced and traditional modalities have failed after a year of expert intervention at a leading military hospital. A 5-minute (16g CO2) D'OXYVA was applied twice a day on a thumb and on the wound for a total of 4 weeks and healing continued long after.
Microcirculation dysfunction is regarded by a growing number of published research papers as the underlying cause of the most widespread health complications for both the young and elderly. Among other things, restrictions in these processes impede the flow of antibodies, white blood cells and platelets, and rob the skin and body of oxygen.
D'OXYVA is a relatively affordable low risk, non-invasive, natural and benign, both adjunct and standalone solution for the forward-looking health facility and patient wanting to significantly reduce cost of treatment and readmission rates, while improving patient compliance.
It is a portable device that you hold in the palm of your hand and each application takes only five minutes. The supersaturated medical gas vapor produced by the D'OXYVA device is almost imperceptible when misted onto the surface of the skin or wound.
The average maintenance dose after complete wound closure may be as low as a single 16g CO2 D'OXYVA cartridge every 2-3 days. The starting and maintenance dose of D'OXYVA should be individualized according to patient characteristics such as goals of the therapy and response, and based on proper diagnosis.
Stopping D'OXYVA after only 4 weeks is not recommended and it may not provide the expected long-term benefits even if major benefits and clinical outcomes were realized. Learn more about the science from expert reviews of D'OXYVA.
The transdermal route with Circularity's platform patented transdermal technology is a Non-Significant Risk Class I medical device available for medical use by prescription under the FDA's Investigational Device Exemption. D'OXYVA inherently carries much lower risks but much greater benefits and cost savings at the same time. Physicians in the United States are allowed to prescribe and conduct research for medical use. Read our regulatory statements.
Several major long term trends are reshaping the health care industry worldwide and D'OXYVA is destined to play a vital role in helping various institutions meet their goals in the near future:
Centers of Excellence Program and Marketing Materials
To introduce D'OXYVA to your patients and test it effectively, chat now or call us or contact your local Circularity-Certified Representative, ask about our Centers of Excellence program, and for the following items:
WARNING! Ask your physician before using D'OXYVA® FOR MEDICAL AND CLINICAL RESEARCH PURPOSES, prescription only. The D'OXYVA transdermal delivery device holds a growing number of Class I (low risk) medical device licenses around the world. Use for non-medical purposes is available over-the-counter (OTC) and in various retail stores online and offline. Circularity's novel D'OXYVA patented transdermal drug delivery pathway with FDA-cleared Medical Carbon Dioxide (UN1013) has not been evaluated yet by the U.S. Food and Drug Administration (FDA) and is not intended to diagnose, treat, cure, or prevent any disease. The information provided on this Website is for educational and research purposes and is not intended to replace medical advice (Learn more).
Related Terms: Autonomic Nervous System, Parasympathetic, Sympathetic, Deoxyhemoglobin, Vasodilation, Skin Perfusion Pressure, Tissue Perfusion, Tissue Oxygenation, Microcirculation, Microvessel Vasodilation, CO2 Natural Vasodilator, Bohr Effect, Haldane Effect, Gas Exchange, Oxygen Transport, Oxygen Curve Shift, Partial Pressure of Oxygen, Hypoxia, Hypoxemia, Blood Flow, Circulation, Endothelial Function, Blood Circulation
In short, based on randomized human clinical trial results, a 16g 5-minute transdermal CO2 delivery with D'OXYVA has recorded industry-leading, hours-long; sustained homeostasis in the autonomic nervous system (ANS), remote vasodilation and vasoconstriction (shunting) all over the body, average 10-25% drop of blood pressure in hypertensive subjects, 80-150% improvement in skin perfusion pressure, tissue perfusion, nutrient delivery, cell respiration, metabolism, and white and red blood cell count in every single subject enrolled. Read principal investigator and expert reviews on the User Feedback page.
Improving the microcirculatory system and nearly every subconscious organ function via the ANS at such elevated levels that has never been reported in published research before is achieved via the so-called supersaturated vaporized carbon dioxide with D'OXYVA's patented system. The autonomic nervous system's peripheral CO2 receptors signal and strengthen the parasympathetic nerve activities.
For example, the Bohr effect (oxygen curve shift) is widely known to facilitate oxygen offloading when the red blood cell's hemoglobin proteins exchange CO2 and H2O, which in turn are contributing to increased endothelial function, blood (SpO2) and tissue (TcPO2) oxygen, and blood flow volume levels throughout the entire cardiovascular system. More
How it works
The resulting supersaturated CO2 and H2O vapor gently sprayed on the skin or wound is a stable solution 50 times more concentrated than competing solutions.